抗纤溶药物能否降低脊柱融合术患儿的输血风险:基于全国数据库的倾向性评分匹配比较
基于美国外科医师学会国家外科质量改进计划儿科数据库2016至2017年数据,纳入6626例脊柱融合术患儿,其中5434例(81%)接受抗纤溶药物、1533例(23%)接受输血。倾向性评分1:1匹配1192对后,抗纤溶药物与围手术期输血降低16%无统计学意义(OR 0.84,95%CI 0.68-1.05,P=0.119),与术后输血降低43%有统计学意义(OR 0.57,95%CI 0.39-0.81,P=0.002)相关;术后癫痫与血栓发生率无差异,总体分别为每万例7.5例和22.5例事件。
要点
- 匹配后抗纤溶药物与术后输血降低43%有统计学意义(OR 0.57,95%CI 0.39-0.81,P=0.002)。
- 匹配后围手术期输血降低16%未达统计学显著(OR 0.84,95%CI 0.68-1.05,P=0.119)。
- 术后癫痫与血栓发生率无差异,总体分别为每万例7.5例和22.5例事件。
核心结论
- 抗纤溶药物似乎可减少脊柱融合术患儿的术后异体输血。
- 血栓栓塞并发症与癫痫等药物不良反应极为罕见,需继续监测。
研究设计与样本
- 回顾性队列研究,数据来自美国外科医师学会国家外科质量改进计划儿科(NSQIP-P)2016和2017年数据库。
- 共纳入6626例脊柱融合术患儿,经单因素分析构建预测抗纤溶药物治疗的倾向性评分模型,行1:1匹配后比较1192对匹配患者的异体红细胞输血率及次要结局。
主要发现
- 6626例患儿中5434例(81%)接受抗纤溶药物,1533例(23%)接受输血。
- 匹配后抗纤溶药物治疗与围手术期输血降低16%相关但无统计学意义(OR 0.84,95%CI 0.68-1.05,P=0.119)。
- 匹配后抗纤溶药物治疗与术后输血降低43%有统计学意义(OR 0.57,95%CI 0.39-0.81,P=0.002)。
- 术后癫痫与血栓发生率无差异,总体分别为每万例7.5例和每万例22.5例事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为回顾性队列。
- 抗纤溶药物对围手术期输血的降低未达统计学显著(OR 0.84,95%CI 0.68-1.05,P=0.119)。
- 药物不良反应如血栓栓塞并发症与癫痫需继续监测。
- 证据等级为3级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Retrospective cohort. OBJECTIVE: To evaluate the effectiveness and safety of antifibrinolytic (AF) agents in reducing perioperative blood transfusion in pediatric patients undergoing spinal fusion. SUMMARY OF BACKGROUND DATA: The potential for AF to decrease bleeding and reduce exposure to allogenic transfusions has led to widespread off-label use in a number of major pediatric surgical procedures. Recent reviews call for improving the body of evidence for their effectiveness and safety in pediatric spinal fusion. METHODS: Children undergoing spinal fusion were identified in the American College of Surgeons National Surgical Quality Improvement Program Pediatric (NSQIP-P) 2016 and 2017 databases. Univariate analyses of patient and perioperative characteristics informed the creation of a propensity score model predicting treatment with AF, followed by 1:1 matching to allow comparison of allogenic red blood cell transfusion rates and secondary outcomes between treated and untreated patients. RESULTS: Of 6626 total patients, 5434 (81%) received AF and 1533 (23%) received a blood transfusion. Analysis of data for 1192 propensity score-matched pairs revealed that treatment with AF was associated with a statistically nonsignificant 16% reduction in perioperative transfusion (OR 0.84, 95% confidence interval 0.68-1.05, P = 0.119) and a statistically significant 43% reduction in postoperative transfusion (OR 0.57, 95% confidence interval 0.39-0.81, P = 0.002). No differences in the incidences of postoperative seizure or thrombosis were observed, with overall rates of 7.5 and 22.5 events per 10,000 patients, respectively. CONCLUSION: AF agents appear to reduce postoperative allogenic transfusion in children undergoing spinal fusion surgery. Adverse drug effects such as thromboembolic complications and seizure were extremely rare and warrant continued monitoring, though this is the largest study to date providing evidence for the safety profile of these drugs. LEVEL OF EVIDENCE: 3.
引用
- Eisler LD, Lenke LG, Sun LS, et al. Do Antifibrinolytic Agents Reduce the Risk of Blood Transfusion in Children Undergoing Spinal Fusion?: A Propensity Score-matched Comparison Using a National Database. Spine (Phila Pa 1976). 2020. PMID: 32675611. doi:10.1097/BRS.0000000000003455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。